Benitec Biopharma Inc. (BNTC)
Benitec Biopharma Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Hayward, CA, US. The stock last traded at $13.48, down 2.18% on the session, giving a market capitalisation of $463.1M. On trailing twelve-month figures it carries a trailing P/E of -12.14, a net margin of -8792.1%. Its beta of 0.26 implies it has historically moved less than the broad market.
Benitec Biopharma Inc. is an emerging biotechnology firm dedicated to advancing groundbreaking genetic medicines. The company specializes in DNA-directed RNA interference (RNAi) based treatments, which it develops to address severe and enduring human conditions. Its pipeline features BB-301, an adeno-associated virus (AAV) gene therapy aimed at treating oculopharyngeal muscular dystrophy, and BB-103, designed to combat chronic hepatitis B virus infection. Established in 1995, Benitec Biopharma's main operations are situated in Hayward, California.
Benitec Biopharma Inc. is most often compared with the following Healthcare names: